Naurex Inc., a clinical stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported positive results from a Phase IIa clinical trial of its lead antidepressant compound, GLYX-13. GLYX-13 is a novel partial agonist of the NMDA receptor.
URL: http://www.topix.com/health/depression/2012/12/novel-nmda-receptor-modulator-significantly-reduces-depression-scores-within-hours?fromrss=1
No comments:
Post a Comment